Media Articles Related to Iquix (Levofloxacin Ophthalmic)
Picture of Bacterial Conjunctivitis (Pink Eye)
Source: MedicineNet sulfamethoxazole Specialty [2010.11.08]
Title: Picture of Bacterial Conjunctivitis (Pink Eye)
Created: 11/8/2010 2:54:00 PM
Last Editorial Review: 11/8/2010 2:54:54 PM
Published Studies Related to Iquix (Levofloxacin Ophthalmic)
Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration. [2010.12]
PURPOSE: To evaluate the time course of drug concentrations achieved in aqueous (AQ), vitreous (V), and serum (S) compartments after oral administration of linezolid and levofloxacin. DESIGN: Randomized, clinical trial... CONCLUSIONS: Single concomitant doses of linezolid and levofloxacin achieved AQ and V concentrations above the minimum inhibitory concentration for 90% of common ocular gram-positive and gram-negative pathogens up to 12 h after administration. The combination of linezolid and levofloxacin represents a viable option for the prophylaxis and management of endophthalmitis.
Short-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface. [2010.12]
PURPOSE: To compare the short-term effects of preserved and unpreserved topical levofloxacin on the ocular surface of preoperative patients with age-related cataracts... CONCLUSION: Regarding the short-term effects on the ocular surface of patients with age-related cataracts, no clinically and statistically significant differences were observed between topical levofloxacin preserved with BOB and its unpreserved counterpart.
Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers. [2010.03]
PURPOSE: This study evaluated the tear concentration and safety of levofloxacin ophthalmic solution 1.5%... CONCLUSION: A single dose of levofloxacin 1.5% produced tear fluid concentrations that were well above the minimum inhibitory concentration90 for typical ocular pathogens and was safe and well tolerated.
A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. [2009.07]
BACKGROUND: To determine the efficacy of conjunctival bacterial eradication following a 1-day, 3-day and 7-day application of topical 0.5% levofloxacin, with and without eyelid scrub, in patients with chronic blepharoconjunctivitis (CBC)... CONCLUSIONS: CBC eyes have a significantly higher number of positive cultures than eyes without CBC. The application of topical 0.5% levofloxacin for at least 3 days provided a significant reduction in the number of positive cultures as well as the number of bacteria harbored on the conjunctival surface.
Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients. [2009.03]
PURPOSE: This study aimed to investigate the rise in aqueous humour (AH) levels of levofloxacin after a specific perioperative pulsed topical drop regimen... CONCLUSIONS: This is the first study to measure AH levels of levofloxacin after postoperative pulsed dosing in humans. Higher AH levels were found than in previously reported studies in which only preoperative drops were given and levels were measured at the time of surgery. Levels of levofloxacin continued to rise for 60 mins after administration of the last postoperative drop, demonstrating that delivery and maintenance of effective antibiotic levels may be achievable with alternative dosing schedules.
Clinical Trials Related to Iquix (Levofloxacin Ophthalmic)
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". [Recruiting]
A multicenter, prospective, non-inferiority, randomized and open clinical trial comparing
levofloxacin with isoniazid in the treatment of latent tuberculosis infection in patients
eligible for liver transplantation.
Patients over 18 years of age on the waiting list for liver transplantation.
Sample size: n=870 patients.
Levofloxacin treatment of latent tuberculosis infection, begun while on the waiting list for
liver transplantation, is safer and not less effective than isoniazid treatment begun after
transplantation when liver function is stable.
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis [Active, not recruiting]
The purpose of this study is to compare the safety and effectiveness of levofloxacin 750 mg
for 2 weeks or 750 mg for 3 weeks, compared to levofloxacin 500 mg for 4 weeks in the
treatment of chronic prostatitis.
Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients [Recruiting]
Fluoroquinolone is a one of the most important drugs for treatment of multidrug-resistant TB
(MDR-TB). Among them, levofloxacin and moxifloxacin has been used most widely. However,
there is no study to directly compare the efficacy of levofloxacin and moxifloxacin among
MDR-TB patients. The investigators will compare the efficacy of levofloxacin and
moxifloxacin through a prospective multicenter randomized open label phase III trial.
A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects [Completed]
The primary objective of the study was to assess the bioequivalence of the oral suspension
formulation, the oral solution formulation, and the marketed tablet formulation of
levofloxacin, with the marketed tablet as the reference.
Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB) [Not yet recruiting]
40 outpatients with exacerbations of Chronic Obstructive Pulmonary Diseases (COPD) will be
enrolled in a multi-centre, open-label, randomised, pilot study. Two treatments will be
compared, ceftidoren 200 mg bid for 5 days and levofloxacin 500 mg once daily for 7 days.
Primary objective of the study is to evaluate the effects of the treatment on serum
inflammatory biomarkers and the secondary objective is to evaluate the clinical and
microbiological efficacy at the Test Of Cure visit (TOC), DAY 7-10 (end of treatment).
The study foresees 4 visits: Visit 1 (enrolment, day 1 of treatment); Visit 2 (day 2-4);
Visit 3 (Test Of Cure-TOC visit, day 7-10 end of treatment), Visit 3 (Late Post Therapy
assessment, Day 28-30).
The primary parameter to test the efficacy of the study medications will be the assessment
of the speed of reduction of inflammatory parameters (CRP, PCT and KL6). Every reduction of
10% will be taken into account. The comparison between treatments will be performed at visit
2 and 3.